Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 5/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1321949 | 0.83 | GAA (0.46) | CDK4CCNE1CDK2JAK1MAP3K5 | |
| SCHEMBL1320006 | 0.78 | GAA (0.44) | JAK1GAA | |
| SCHEMBL20798098 | 0.74 | RAB9A (0.49) | CDK4CCNE1CDK2MAP3K5L3MBTL1 | |
| SCHEMBL3146252 | 0.74 | KDM4E (0.39) | CDK4CCNE1CDK2JAK1MAP3K5 | |
| SCHEMBL18367355 | 0.74 | MGLL (0.50) | MGLLL3MBTL1PDE10AGAA | |
| SCHEMBL3141656 | 0.73 | MAP3K5 (0.38) | CDK4CCNE1CDK2MAP3K5TGFBR1 | |
| SCHEMBL3141609 | 0.73 | MAP3K5 (0.36) | CDK4CCNE1CDK2JAK1MAP3K5 | |
| SCHEMBL30587619 | 0.72 | MGLL (0.47) | CDK4CDK2MGLLL3MBTL1PDE10A | |
| SCHEMBL3146395 | 0.70 | MAP3K5 (0.38) | CDK4CCNE1CDK2JAK1MAP3K5 | |
| SCHEMBL2364683 | 0.69 | PIK3CA (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018208-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20130143889-A1 | Heterocycles As Potassium Channel Modulators | ICAGEN INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8431608-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2178373-B1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN INC (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-2536718-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8058274-B2 | Heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| WO-2011102964-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2178373-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090062290-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2009026254-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143889-A1 | Heterocycles As Potassium Channel Modulators | KCNK10, KCNK9, KCNJ2 | CDK4 819/4885CCNE1 4260/4885CDK2 1365/4885 |
| US-20090062290-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK2, KCNK17 | CDK4 702/4885CCNE1 4203/4885CDK2 1165/4885 |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK2, KCNK17 | CDK4 702/4885CCNE1 4203/4885CDK2 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.